Department of Pathology, Toho University Medical Center, Sakura Hospital, Sakura, Japan; Department of Surgical Pathology, Toho University Medical Center, Sakura Hospital, Sakura, Japan; Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan.
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Pathology, Kawakita General Hospital, Tokyo, Japan.
Pathol Res Pract. 2024 Aug;260:155376. doi: 10.1016/j.prp.2024.155376. Epub 2024 May 29.
Lipogenic and fibrous tumors are thought to originate from CD34-positive stromal fibroblastic/fibrocystic cells. Well-differentiated lipogenic tumors typically express CD34, whereas dedifferentiated liposarcoma (DDLPS) often loses it. We conducted survival analyses involving 59 patients with DDLPS. Males comprised 53% of the cohort, and the median age at the time of wide resection of primary DDLPS was 60 years. Loss of CD34 expression was defined as when ≥50% of the dedifferentiated area was immunohistochemically negative for CD34. As a result, 39 of the 59 patients showed loss of CD34 expression during the initial operation for DDLPS. In the univariate analyses, the tumor site in the retroperitoneum/abdominal cavity and loss of CD34 expression were significantly associated with poor overall survival. In the multivariate analyses, loss of CD34 expression (HR = 2.26; 95% CI = 1.02-5.02; p = 0.04) and the tumor site in the retroperitoneum/abdominal cavity (HR = 3.11; 95% CI = 1.09-8.86; p = 0.03) were retained as independent prognostic factors. Six CD34-positive cases lost CD34 expression when they developed metastasis and/or local recurrence, suggesting that the loss was associated with the later stage of the tumor. Therefore, an association existed between the loss of CD34 expression and clinicopathological behaviors such as poorer prognoses and recurrence.
成脂性和纤维性肿瘤被认为起源于 CD34 阳性的间质纤维母细胞/纤维囊性细胞。分化良好的成脂性肿瘤通常表达 CD34，而去分化脂肪肉瘤（DDLPS）通常会丢失它。我们对 59 例 DDLPS 患者进行了生存分析。男性占队列的 53%，广泛切除原发性 DDLPS 时的中位年龄为 60 岁。CD34 表达缺失的定义为当≥50%的去分化区域免疫组化染色 CD34 阴性时。结果，在 59 例患者中，有 39 例在初始手术时显示 DDLPS 的 CD34 表达缺失。在单因素分析中，腹膜后/腹腔内肿瘤部位和 CD34 表达缺失与总生存不良显著相关。在多因素分析中，CD34 表达缺失（HR=2.26；95%CI=1.02-5.02；p=0.04）和腹膜后/腹腔内肿瘤部位（HR=3.11；95%CI=1.09-8.86；p=0.03）是保留的独立预后因素。6 例 CD34 阳性病例在发生转移和/或局部复发时失去 CD34 表达，提示该缺失与肿瘤的晚期有关。因此，CD34 表达缺失与预后和复发等临床病理行为之间存在关联。
